12:00 AM
Apr 25, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Pandemrix regulatory update

EMA's CHMP recommended changes to the label of GlaxoSmithKline's Pandemrix advising that health professionals perform an individual benefit-risk assessment taking into account the potential increased risk of narcolepsy in children and adolescents when prescribing the...

Read the full 153 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >